Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07217158 · ClinicalTrials.gov registry record
Role of ROS and cAMP-PKA Biomarkers in ADPKD
A clinical trial of Autosomal Dominant Polycystic Kidney Disease, sponsored by Mayo Clinic.
- Active
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT07217158 is a study of Autosomal Dominant Polycystic Kidney Disease that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 100 participants, below the 150-participant average among 9 other Autosomal Dominant Polycystic Kidney Disease trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07217158, a study of Autosomal Dominant Polycystic Kidney Disease, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective is to determine the prognostic value of markers of ROS and cAMP-PKA signaling to assess disease severity and progression in patients with ADPKD.
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2027-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07217158
The ClinicalTrials.gov registry entry for NCT07217158 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 150-participant average among 9 other Autosomal Dominant Polycystic Kidney Disease trials with a reported enrollment target (33% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autosomal Dominant Polycystic Kidney Disease appearing as the primary indexed condition, and to 0 interventions.
NCT07217158 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT07217158 about?
NCT07217158 is a clinical study titled "Role of ROS and cAMP-PKA Biomarkers in ADPKD". The primary objective is to determine the prognostic value of markers of ROS and cAMP-PKA signaling to assess disease severity and progression in patients with ADPKD.
What is the current status of trial NCT07217158?
This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2023-07-01. Estimated completion is 2027-06-30.
What conditions does trial NCT07217158 study?
This clinical trial studies the following conditions: Autosomal Dominant Polycystic Kidney Disease.
Who is sponsoring clinical trial NCT07217158?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07217158 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autosomal Dominant Polycystic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
RECRUITING
-
NOX4 and Related Biomarkers in ADPKD
RECRUITING
-
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
RECRUITING · Phase 2
-
Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease
RECRUITING · Phase 1
-
A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD
ACTIVE NOT RECRUITING
-
Intrarenal Microvasculature in ADPKD
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.